---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-070134"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:02:58.010121+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bluejay Diagnostics Q3 net loss widens to $3.0M; cash $13.3M; FDA submission planned H1 2023

## Summary
- Net loss for Q3 2022 was $3.0M ($0.15 per share) vs $1.2M ($0.11 per share) in Q3 2021.
- Cash and cash equivalents at Sep 30, 2022: $13.3M, down from $19.0M at Dec 31, 2021; cash expected to fund operations for 12 months.
- R&D expenses rose to $1.4M in Q3 2022 from $443k in Q3 2021 due to clinical program expansion and scale-up manufacturing.
- No product sales in Q3; small non-recurring sale in Q2 2022 generated ~$250k revenue for nine months.
- Company plans to submit De Novo application for Symphony IL-6 test with FDA in first half of 2023.

## SEC filing metadata
- accession: 0001213900-22-070134
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390022070134/0001213900-22-070134-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390022070134/ea168158-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-070134
- JSON: https://secwatch.observer/filing/0001213900-22-070134.json
- Plain text: https://secwatch.observer/filing/0001213900-22-070134.txt

## Key facts
- Earnings Releases
  Bluejay Diagnostics, Inc. reported nine months ended September 30, 2022 results: net income $6.9 million, EPS $0.34 per share.
  - Period: nine months ended September 30, 2022
  - Net income: $6.9 million
  - EPS: $0.34 per share
  - Result: reported results
  source text: The net loss for the three and nine months ended September 30, 2022 was $3.0 million and $6.9 million, or $0.15 and $0.34 per share, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704287/000121390022070134/0001213900-22-070134-index.htm
- Earnings Releases
  Bluejay Diagnostics, Inc. reported quarter ended September 30, 2022 results: net income $3.0 million, EPS $0.15 per share.
  - Period: quarter ended September 30, 2022
  - Net income: $3.0 million
  - EPS: $0.15 per share
  - Result: reported results
  source text: The net loss for the three and nine months ended September 30, 2022 was $3.0 million and $6.9 million, or $0.15 and $0.34 per share, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704287/000121390022070134/0001213900-22-070134-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.